Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma

J. M. Connors, Paul Klimo, R. N. Fairey, N. Voss

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Study objective: To determine the efficacy and toxicity of brief chemotherapy and involved field radiation therapy for treatment of limited-stage, histologically aggressive malignant lymphoma. Design: Single-arm prospective trial. Setting: Comprehensive cancer treatment center serving the entire population of British Columbia. Patients: Consecutive enrollment of 78 patients ranging in age from 21 to 82 years (median, 64) with limited-stage (no B symptoms, Ann Arbor stage I or II, tumors less than 10 cm in diameter), diffuse large cell, mixed or immunoblatic histologic characteristics of malignant lymphoma seen at our institution between May 1980 and December 1984. All eligible patients were evaluated for response and relapse-free and overall survival. Interventions: Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for three cycles followed by involved field radiation therapy to the original site of disease in a dose equivalent to 3000 cGy in ten fractions. Main Results: The complete response rate was 99% (77 of 78 patients). With a median follow-up off treatment of 30 months the actuarial relapse-free survival is 84% and the overall survival is 85%. No deaths due to toxicity occurred. Conclusions: Brief chemotherapy and involved field radiation therapy is highly successful treatment for patients with limited-stage, histologically aggressive malignant lymphoma. Toxicity of this approach is acceptable, even in the elderly. Staging laparotomy is not needed to select these patients. Future trials should incorporate more effective chemotherapy programs.

Original languageEnglish (US)
Pages (from-to)25-30
Number of pages6
JournalAnnals of Internal Medicine
Volume107
Issue number1
DOIs
StatePublished - Jan 1 1987
Externally publishedYes

Fingerprint

Lymphoma
Radiotherapy
Drug Therapy
Survival
Recurrence
British Columbia
Vincristine
Therapeutics
Prednisone
Doxorubicin
Cyclophosphamide
Laparotomy
Neoplasms
Population

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma. / Connors, J. M.; Klimo, Paul; Fairey, R. N.; Voss, N.

In: Annals of Internal Medicine, Vol. 107, No. 1, 01.01.1987, p. 25-30.

Research output: Contribution to journalArticle

@article{db934f489acb4c8bb3b5ee7b9698a3a4,
title = "Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma",
abstract = "Study objective: To determine the efficacy and toxicity of brief chemotherapy and involved field radiation therapy for treatment of limited-stage, histologically aggressive malignant lymphoma. Design: Single-arm prospective trial. Setting: Comprehensive cancer treatment center serving the entire population of British Columbia. Patients: Consecutive enrollment of 78 patients ranging in age from 21 to 82 years (median, 64) with limited-stage (no B symptoms, Ann Arbor stage I or II, tumors less than 10 cm in diameter), diffuse large cell, mixed or immunoblatic histologic characteristics of malignant lymphoma seen at our institution between May 1980 and December 1984. All eligible patients were evaluated for response and relapse-free and overall survival. Interventions: Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for three cycles followed by involved field radiation therapy to the original site of disease in a dose equivalent to 3000 cGy in ten fractions. Main Results: The complete response rate was 99{\%} (77 of 78 patients). With a median follow-up off treatment of 30 months the actuarial relapse-free survival is 84{\%} and the overall survival is 85{\%}. No deaths due to toxicity occurred. Conclusions: Brief chemotherapy and involved field radiation therapy is highly successful treatment for patients with limited-stage, histologically aggressive malignant lymphoma. Toxicity of this approach is acceptable, even in the elderly. Staging laparotomy is not needed to select these patients. Future trials should incorporate more effective chemotherapy programs.",
author = "Connors, {J. M.} and Paul Klimo and Fairey, {R. N.} and N. Voss",
year = "1987",
month = "1",
day = "1",
doi = "10.7326/0003-4819-107-1-25",
language = "English (US)",
volume = "107",
pages = "25--30",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "1",

}

TY - JOUR

T1 - Brief chemotherapy and involved field radiation therapy for limited-stage, histologically aggressive lymphoma

AU - Connors, J. M.

AU - Klimo, Paul

AU - Fairey, R. N.

AU - Voss, N.

PY - 1987/1/1

Y1 - 1987/1/1

N2 - Study objective: To determine the efficacy and toxicity of brief chemotherapy and involved field radiation therapy for treatment of limited-stage, histologically aggressive malignant lymphoma. Design: Single-arm prospective trial. Setting: Comprehensive cancer treatment center serving the entire population of British Columbia. Patients: Consecutive enrollment of 78 patients ranging in age from 21 to 82 years (median, 64) with limited-stage (no B symptoms, Ann Arbor stage I or II, tumors less than 10 cm in diameter), diffuse large cell, mixed or immunoblatic histologic characteristics of malignant lymphoma seen at our institution between May 1980 and December 1984. All eligible patients were evaluated for response and relapse-free and overall survival. Interventions: Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for three cycles followed by involved field radiation therapy to the original site of disease in a dose equivalent to 3000 cGy in ten fractions. Main Results: The complete response rate was 99% (77 of 78 patients). With a median follow-up off treatment of 30 months the actuarial relapse-free survival is 84% and the overall survival is 85%. No deaths due to toxicity occurred. Conclusions: Brief chemotherapy and involved field radiation therapy is highly successful treatment for patients with limited-stage, histologically aggressive malignant lymphoma. Toxicity of this approach is acceptable, even in the elderly. Staging laparotomy is not needed to select these patients. Future trials should incorporate more effective chemotherapy programs.

AB - Study objective: To determine the efficacy and toxicity of brief chemotherapy and involved field radiation therapy for treatment of limited-stage, histologically aggressive malignant lymphoma. Design: Single-arm prospective trial. Setting: Comprehensive cancer treatment center serving the entire population of British Columbia. Patients: Consecutive enrollment of 78 patients ranging in age from 21 to 82 years (median, 64) with limited-stage (no B symptoms, Ann Arbor stage I or II, tumors less than 10 cm in diameter), diffuse large cell, mixed or immunoblatic histologic characteristics of malignant lymphoma seen at our institution between May 1980 and December 1984. All eligible patients were evaluated for response and relapse-free and overall survival. Interventions: Chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) for three cycles followed by involved field radiation therapy to the original site of disease in a dose equivalent to 3000 cGy in ten fractions. Main Results: The complete response rate was 99% (77 of 78 patients). With a median follow-up off treatment of 30 months the actuarial relapse-free survival is 84% and the overall survival is 85%. No deaths due to toxicity occurred. Conclusions: Brief chemotherapy and involved field radiation therapy is highly successful treatment for patients with limited-stage, histologically aggressive malignant lymphoma. Toxicity of this approach is acceptable, even in the elderly. Staging laparotomy is not needed to select these patients. Future trials should incorporate more effective chemotherapy programs.

UR - http://www.scopus.com/inward/record.url?scp=0023261426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023261426&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-107-1-25

DO - 10.7326/0003-4819-107-1-25

M3 - Article

VL - 107

SP - 25

EP - 30

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 1

ER -